JDRF
JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our plan ensures that there will be an ongoing stream of life-changing therapies moving from development through to the marketplace that lessen the impact of T1D. We want to keep people with T1D healthy and safe today until we reach our ultimate goal of a cure and universal prevention of T1D, and turn Type One into Type None. JDRF collaborates with a wide spectrum of partners at every stage of the drug and device delivery pipeline and is the only organization with the scientific resources, regulatory influence, and a strategic plan to deliver a world without T1D. JDRF’s influence and leadership extends beyond funding research. We strategically partner with industry, governments, foundations, academia, and clinicians, because curing T1D is a global, coordinated effort with JDRF leading the effort.
JDRF PERSONNEL WORKING ON SOPHIA
Olivier Arnaud
Sanjoy Dutta
Jeannette Soderberg
Jonathan Rosen
Type 1 Diabetes Exchange T1DE
T1D Exchange Quality Improvement (QI) joins a learning collaborative with a data platform to redefine best practices, enhance the quality of care, and ultimately generate better outcomes. This model helps fill the gap between the surge of diabetes innovation, drugs, and technology, and the lack of corresponding uptake or benefit by patients. The Collaborative brings together over 12 clinics, situated across the US and treating more than 28,000 individuals with type 1 diabetes. The Collaborative has achieved unprecedented success because it relies on an embedded and systemic approach: individual providers are empowered to identify areas of unmet need within their clinic. They make small changes in care that scale up through the Collaborative to create best practices, which are then shared among and implemented by members at other clinics. Decision-making is facilitated by electronic record and health data on all patients that is uploaded from clinics to the new T1D Exchange QI platform. After analysis and benchmarking, each clinic has a clearer picture of how their patient populations are faring based on the treatments and interventions being adopted and thus, how and where to target change efforts to improve outcomes for the subpopulations most at risk.
T1DE PERSONNEL WORKING ON SOPHIA
Rebecca Parkes
Obesity Action Coalition OAC
The Obesity Action Coalition (OAC) is a more than 66,000 member-strong United States based 501(c)(3) non-profit organization dedicated to giving a voice to the individual affected by the disease of obesity and helping individuals along their journey toward better health through education, advocacy and support. Our core focuses are to raise awareness and improve access to the prevention and treatment of obesity, provide evidence-based education on obesity and its treatments, fight to eliminate weight bias and discrimination, elevate the conversation of weight and its impact on health and offer a community of support for the individual affected.
OAC PERSONNEL WORKING ON SOPHIA
Joseph Nadglowski